Treatment of Sickle Cell Leg Ulcers with Pentoxifylline

Frost, Marc L.; Treadwell, Patricia

doi:10.1111/j.1365-4362.1990.tb04768.x

Cited by 30 publications

(11 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A single case in 1990 reported that pentoxifylline by oral route (400 mg, 3/day) was effective on an SCLU, with complete healing in 3 months. 51 One patient with an SCLU was treated with bosentan, an endothelin receptor antagonist, for pulmonary hypertension. 52 The ulcer healed in 3 weeks, without relapse for 10 months.…”

Section: Systemic Treatmentmentioning

confidence: 99%

Leg Ulcers in Sickle-Cell Disease: Treatment Update

Monfort

Senet

2020

Advances in Wound Care

View full text Add to dashboard Cite

Sickle-cell leg ulcers (SCLUs) are a severe, chronic, and recurrent complication of sickle-cell disease (SCD). There are no official recommendations for treatment. Recent Advances: Only a few studies with a high level of evidence have been conducted to evaluate treatment of SCLUs. However, several studies have been conducted with a high level of evidence to evaluate the efficacy of treatments in venous leg ulcers, and SCLUs could benefit from these treatments, especially when a venous incompetence or an edema is associated. Pathophysiology of SCLUs includes a vasculopathy related to chronic hemolysis and an endothelial dysfunction, which could be therapeutic approaches to SCLU treatment. Critical Issues: Therapeutic approaches to SCLUs can target SCD on the one hand and skin healing and associated aggravating factors on the other. A review of the literature found only case series and six randomized controlled trials; some offered encouraging results, but most had serious biases. Clinical trials specifically targeting SCLUs are difficult to realize because of the small number of affected patients, in comparison with patients with leg ulcers from other causes. Future Direction: Treating SCLUs remains a challenge. Data in the literature are currently insufficient to offer clear treatment guidelines because of several biases in controlled studies. New studies are under way to assess the efficacy of topical treatments and describe the microbiome of SCLUs. Prevention of SCLU recurrence should be assessed in future clinical trials because the high risk of recurrence is an unsolved critical issue.

show abstract

Section: Systemic Treatmentmentioning

confidence: 99%

Leg Ulcers in Sickle-Cell Disease: Treatment Update

Monfort

Senet

2020

Advances in Wound Care

View full text Add to dashboard Cite

show abstract

“…Pharmaceutical interventions a. Systemic pharmaceutical interventions: i. vascular drugs (such as pentoxifylline (blood viscosityreducing agent) (Frost 1990), isoxsuprine hydrochloride (β-adrenergic receptor stimulant) (Serjeant 1977), xanthinol nicotinate (vasodilator) (Afifi 1979)); ii. antioxidant agents (such as L-carnitine) (Harrel 1990;Serjeant 1997); iii.…”

Section: Description Of the Interventionmentioning

confidence: 99%

Interventions for treating leg ulcers in people with sickle cell disease

Martí‐Carvajal¹,

Knight‐Madden

Martinez-Zapata

2014

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…19 Its use in sickle-cell ulcers had already been proposed in 1990, on the basis of its effects in reducing sickling of red blood cells in vitro and for resolution of vessel-occlusive crises in SCD (evidence level C, recommendation level 4). 20 This drug has been strongly recommended for treatment of venous stasis ulcers (evidence level B, recommendation level 1) and some authors consider that it should also be used in patients with sickle cell ulcers because of the high frequency of CVD observed in these cases. 5 The same group 5 also suggests using a biological skin substitute (Apligraf®, Organogenesis Inc., Canton, Massachusetts), composed of cultured keratinocytes and fibroblasts on a collagen scaffold, for treatment of leg ulcers in patients with SCD and CVD, who have not responded to conventional treatments after 4 to 6 weeks.…”

Section: Treatment Of Cvdmentioning

confidence: 99%

Úlceras de perna em pacientes com anemia falciforme

et al. 2020

View full text Add to dashboard Cite

Resumo As úlceras de perna são as complicações cutâneas mais comuns em pacientes com anemia falciforme. Acometem principalmente indivíduos homozigotos e são lesões de difícil cicatrização e recidivantes, com impactos físicos, psicológicos e econômicos. Neste trabalho, discutimos a apresentação clínica, o diagnóstico, a fisiopatologia das úlceras falcêmicas e as suas implicações sobre a terapêutica.

show abstract

Treatment of Sickle Cell Leg Ulcers with Pentoxifylline

Cited by 30 publications

References 10 publications

Leg Ulcers in Sickle-Cell Disease: Treatment Update

Leg Ulcers in Sickle-Cell Disease: Treatment Update

Interventions for treating leg ulcers in people with sickle cell disease

Úlceras de perna em pacientes com anemia falciforme

Contact Info

Product

Resources

About